← Russell 3000 cross-section

PTCT PTC THERAPEUTICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$6.0bn
Revenue TTM
$1.0bn
Net income TTM
$-38m
Free cash flow
$-40m
Composite score
55.4
Sector rank
#967

Valuation

P / E
EV / EBITDA
23.6
EV / sales
4.2
FCF yield
-0.67%
Earnings yield vs 10-yr
-5.37pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3.8%
EBITDA margin
17.9%
ROE
23.2%
ROIC
Revenue growth
-42.8%

Insider activity, last 90 days

Net open-market
$-19.75m
Buyers
0
Sellers
8

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

With the expiration of this orphan drug exclusivity, we have seen an increase in competition from generics, which has, and we expect will continue to have, a negative impact on Emflaza net product revenue. Our revenues were primarily generated from sales of Sephience for the treatment of PKU in the U.S. and EEA, Translarna for the treatment of nmDMD in countries where we were able to obtain acceptable commercial pricing and reimbursement terms and in select countries where we are permitted to distribute Translarna under our early access programs, or EAP, programs or through similar styled programs, and from sales of Emflaza for the treatment of DMD in the United States. …PTC THERAPEUTICS, INC., 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →